Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer

Choi, Seong Ho; Byeon, Hyeong Jun; Choi, Ji Su; Thao, Lequang; Kim, In-Soo; Lee, Eun Seong; Shin, Beom Soo; Lee, Kang Choon; Youn, Yu Seok

doi:10.1016/j.jconrel.2014.11.008

Cited by 132 publications

(67 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a recent study argue against the involvement of SPARC in nab-paclitaxel treatment of metastatic breast cancer [280]. More recent examples are biodegradable albumin-based nanoparticles containing contrast agents for magnetic resonance imaging of hepatocellular carcinoma [281], iron-oxide containing magnetic nanoparticles for tumor imaging [227], anti-elastin antibody and EDTA-loaded nanoparticles for targeting to degraded elastic lamina of vascular diseases [228,229] as well as inhalable nanoparticles containing drugs targeting lung cancer [230]. Examples of therapeutic molecules that have been encapsulated in albumin-based nanoparticles are listed in Table 2.…”

Section: Albumin-based Nanoparticlesmentioning

confidence: 99%

The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery

Bern

Sand

Nilsen

et al. 2015

Journal of Controlled Release

162

135

View full text Add to dashboard Cite

Section: Albumin-based Nanoparticlesmentioning

confidence: 99%

The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery

Bern

Sand

Nilsen

et al. 2015

Journal of Controlled Release

162

135

View full text Add to dashboard Cite

Section: Othersmentioning

confidence: 99%

“…In a recent study, a hydrophobic selfassembled nanoparticles consisting of doxorubicin, octyl aldehyde and human serum albumin (HSA) were functionalized with TRAIL protein to increase synergistic apoptotic effect [69]. Using an aerosolizer, TRAIL-doxorubicin-HSA conjugates were well deposited in mouse lung and demonstrated gradual release of drug over 3 days [69]. Recently, Taratula and co-workers explored the feasibility of mesoporous silica nanoparticles (MSN) as carrier for inhalation therapy with specific targeting to lung cancer [70].…”

Section: Othersmentioning

confidence: 99%

Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges

Lee

Loo

Traini

et al. 2015

Asian Journal of Pharmaceutical Sciences

151

View full text Add to dashboard Cite

Ever since the success of developing inhalable insulin, drug delivery via pulmonary administration has become an attractive route to treat chronic diseases. Pulmonary delivery system for nanotechnology is a relatively new concept especially when applicable to lung cancer therapy. Nano-based systems such as liposome, polymeric nanoparticles or micelles are strategically designed to enhance the therapeutic index of anti-cancer drugs through improvement of their bioavailability, stability and residency at targeted lung regions. Along with these benefits, nano-based systems also provide additional diagnostic advantages during lung cancer treatment, including imaging, screening and drug tracking. Nevertheless, delivery of nano-based drugs via pulmonary administration for lung cancer therapy is still in its infancy and numerous challenges are expected. Pharmacology, immunology, toxicology and large-scale manufacturing (stability and activity of drugs) are some aspects in nanotechnology that should be taken into consideration for the development of inhalable nano-based chemotherapeutic drugs. This review will focus on the current inhalable nano-based drugs for lung cancer treatment.

show abstract

“…Albumin is an abundant component of lung-lining fluid, with a concentration approximately 10% of that found in serum,6 and has favorable biocompatibility. Self-assembling albumin NPs containing doxorubicin have been shown to significantly reduce tumor size following pulmonary administration in a mouse model of lung cancer 7. Tacrolimus, an insoluble therapeutic agent, has been encapsulated in albumin NPs for pulmonary fibrosis therapy, and these NPs have remarkable antifibrotic efficacy in mice 8.…”

Section: Introductionmentioning

confidence: 99%

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

Lin¹,

Lee²,

Zhang³

et al. 2016

DDDT

View full text Add to dashboard Cite

Fenretinide is a novel anticancer agent reported to exhibit anti-invasive and antimetastatic activities. It has also been shown to improve obesity and diabetes, although the effects of fenretinide on hypertension are still unknown, and the detailed mechanisms remain unclear. In this study, we have shown that treatment with lipopolysaccharide (LPS) decreased the expression of peroxisome proliferator-activated receptor γ (PPARγ) in RAW264.7 macrophages, and pretreatment with fenretinide reversed the effect of LPS on PPARγ expression. In addition, LPS-induced pro-inflammatory cytokine production, including tumor necrosis factor-α, interleukin 6, and monocyte chemoattractant protein 1 were dose-dependently reversed by fenretinide, and the effects of fenretinide on LPS-induced pro-inflammatory cytokine production were blocked by treatment with PPARγ antagonist. Moreover, fenretinide decreased LPS-induced inducible nitric oxide synthase expression and nitrogen oxide production. These effects were blocked by the pretreatment with PPARγ antagonist in a dose-dependent manner, indicating fenretinide activated PPARγ to exert anti-inflammation activity. In view of the role of inflammation in hypertension and the anti-inflammatory action of fenretinide, we found that administration of fenretinide in spontaneously hypertensive rats significantly decreased blood pressure. Taken together, these results indicate that fenretinide might be a potent antihypertensive agent that works by suppressing inflammation via activating PPARγ.

show abstract

Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer

Cited by 132 publications

References 37 publications

The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery

The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery

Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

Contact Info

Product

Resources

About